CJC-1295 with DAC 5mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of CJC-1295 with DAC supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF102025048

Key analytical results include:

• Assay Content (CJC-1295 DAC): 5.50 mg
• Identification – Retention Time: 0.997
• Identification – Spectrum: 994
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: detected but below 0.01 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

CJC-1295 with DAC is a synthetic peptide research compound frequently studied in laboratory environments focused on endocrine signalling and peptide-receptor interaction pathways.

The compound represents a modified analogue of growth hormone releasing hormone (GHRH) that includes a Drug Affinity Complex (DAC), a structural modification that extends peptide stability in experimental models.

This preparation contains 5 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide sequence and stable analytical profile, CJC-1295 with DAC has become a widely referenced compound in experimental endocrine signalling research.

Compound Overview

CJC-1295 with DAC is a modified growth hormone releasing hormone analogue designed for biochemical research exploring peptide-mediated endocrine signalling pathways.

The addition of the Drug Affinity Complex (DAC) modifies the peptide structure, allowing researchers to investigate prolonged receptor interaction behaviour in experimental models.

Within laboratory research environments, the compound is frequently studied in relation to receptor-mediated signalling cascades and hormonal regulatory mechanisms.

The defined peptide structure enables scientists to analyse peptide-receptor interaction dynamics and endocrine regulatory signalling systems.

Historical Background and Scientific Context

Scientific interest in hormone-regulating peptides increased rapidly during the late twentieth century as advances in molecular biology enabled researchers to analyse endocrine signalling pathways at the receptor level.

Growth hormone releasing hormone analogues were developed as research tools to investigate hormone regulation and peptide-receptor signalling mechanisms.

Later structural modifications, including the Drug Affinity Complex used in CJC-1295 DAC, were introduced to study extended peptide stability and receptor interaction behaviour in experimental models.

These compounds are now widely used in laboratory research exploring endocrine regulatory systems and peptide signalling networks.

Mechanistic Focus in Research

Within experimental laboratory environments, CJC-1295 with DAC is frequently studied in relation to endocrine signalling and peptide-receptor interaction pathways.

Research investigations commonly explore the compound in experimental models examining:

• Growth hormone releasing hormone receptor signalling
• Peptide-mediated endocrine signalling pathways
• Hormonal regulatory network modelling
• Intracellular signalling cascade dynamics
• Comparative peptide signalling research
• Receptor activation mechanisms
• Molecular endocrine pathway analysis

These experimental models allow scientists to investigate molecular regulatory mechanisms influencing endocrine signalling and peptide-receptor interactions.

Research Applications

In controlled research environments, CJC-1295 with DAC may be utilised in experimental models designed to explore endocrine signalling systems and peptide-mediated receptor pathways.

Examples of research applications include:

• Endocrine signalling pathway investigation
• Peptide-receptor interaction research
• Hormonal regulatory mechanism studies
• Cell signalling analysis
• Comparative peptide interaction modelling
• Molecular endocrine pathway research
• Controlled in vitro peptide signalling studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Verified and analysed with Liquilabs s.r.o. Czechia
• Greater than 99.8 percent purity with validated assay content
• No detectable heavy metals or microbial contamination
• Endotoxin detected but below 0.01 EU per mg
• Batch GF102025048 – Published October 2025
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.